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Sentinel lymph node biopsy (SLNB) has been widely
accepted and used to determine axillary lymph node
status for the past decade.
1,2 Consequently, SLNB
has been a valuable method for determining patients’
treatment options, such as whether or not a complete
axillary lymph node dissection (CALND) would be
necessary for local control and correct staging of the
breast cancer patient. When extraordinary cases
materialize, it is often difﬁcult to determine a com-
mon treatment pathway for the patient. The rare
ﬁnding and subsequent treatment of the intramam-
mary sentinel lymph node (IntraMSLN) metastasis
has become such in recent years. The argument lies in
whether or not a positive IntraMSLN warrants a
CALND or whether it can be spared, compared with
a positive axillary sentinel lymph node, which would
warrant a CALND.
Two studies have examined the prognostic signiﬁ-
cance of positive intramammary lymph nodes (In-
traMLN) from the presentinel node era and
postulated treatment recommendations. Shen et al.
reported that IntraMLN metastasis was an indepen-
dent predictor of a worsened prognosis and that pa-
tients with IntraMLN metastases were signiﬁcantly
associated with a shorter disease-free survival and
overall survival. Therefore, CALND was warranted.
3
Similarly, Guth et al. reported that a CALND should
be recommended for patients with positive Intra-
MLNs based on their ﬁndings that patients with In-
traMLNs had more aggressive cancers including
higher rates of lymphovascular invasion and axillary
nodal disease, and these patients were more fre-
quently multifocal and had a higher grade and stage
of disease on ﬁnal analysis.
4
In contrast to previous studies reported in which
IntraMLNs were detected on ﬁnal pathology review,
Dr. Intra and colleagues recently reviewed their
institution’s data for patients with IntraMSLNs de-
tected with mapping techniques. Twenty-two patients
were found to have IntraMSLN and axillary sentinel
lymph nodes (axSLN) present. Of the 22 patients, 15
had both IntraMSLNs and axSLNs excised, of which
six IntraMSLNs were positive and all axSLNs were
negative. In addition, two of the six patients had po-
sitive IntraMSLNs, and one patient with a negative
axSLN had a CALND; in all three cases all axillary
nodes were negative. After 24 months they found no
recurrences. Based on these ﬁndings, Dr. Intra’s
group argued that when both IntraMSLNs and ax-
SLNs are present then both should be biopsied and
that a CALND should be based on the status of the
axSLNs.
5 Dr. Intra and colleagues raise the question
whether a CALND on patients should be done when
positive or negative IntraMSLNs are found when
axSLNs are not localized. The answer to which this
author’s recommendation would be, yes perform the
CALND due to mapping failure of the axilla.
Between September 1994 and October 2005, 15,000
patients’ records in the Moﬃtt Cancer Center Breast
Cancer database were retrospectively reviewed fol-
lowing institutional review board (IRB) approval.
Only patients with T1–T2 invasive breast tumors
were included. Ninety-one patients were identified
with having IntraMLNs, of which eight patients (9%)
had isolated IntraMLNs. All eight patients with iso-
lated intraMLNs had negative axillary contents on
pathology. Eighteen of the 91 patients (21%) had
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1273IntraMLN with axillary metastases. Sixty-two of 91
patients (69%) had a negative IntraMLN. There were
502 patients identified with (N1), axillary nodal
metastasis and compared with patients with isolated
IntraMLN positive patients. Patients with isolated
IntraMLN metastases had 0 of 8 recurrences and 0 of
8 deaths after an average follow-up time of
2.63 years. Patients with solitary axillary metastasis
had 36 to 502 recurrence (7%) and 44 of 502 (9%)
died after an average of 2.0 years follow-up. When an
isolated positive IntraMLN is found, these data
suggest an improved prognosis over those patients
with an isolated axillary SLN and would not be
deemed a high-risk patient for metastasis to the
remaining nodes in the axilla.
This Moﬃtt Cancer Center series of IntraMSLNs
reported at the 2005 Society of Surgical Oncology
conference demonstrated that a positive isolated In-
traMSLN compared with an isolated positive axSLN,
actually had an improved prognosis. These data
would conﬁrm the study and recommendation of
Intra et al.
5 that a positive IntraMSLN with negative
axSNL would not warrant CALND nor should it
predict a worse prognosis than isolated axillary nodal
disease.
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